ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 219 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $5,084,000 | -34.8% | 75,000 | -32.3% | 0.74% | -29.7% |
| Q4 2016 | $7,793,000 | -0.9% | 110,842 | 0.0% | 1.05% | +21.1% |
| Q3 2016 | $7,863,000 | +45.0% | 110,842 | 0.0% | 0.87% | +12.7% |
| Q2 2016 | $5,421,000 | -21.8% | 110,842 | +1.2% | 0.77% | -26.3% |
| Q1 2016 | $6,932,000 | -43.6% | 109,500 | 0.0% | 1.04% | -29.0% |
| Q4 2015 | $12,284,000 | +16.5% | 109,500 | 0.0% | 1.47% | -12.7% |
| Q3 2015 | $10,546,000 | +1.0% | 109,500 | +7.4% | 1.68% | +21.2% |
| Q2 2015 | $10,444,000 | +64.9% | 102,000 | 0.0% | 1.39% | +41.9% |
| Q1 2015 | $6,333,000 | +20.3% | 102,000 | -15.0% | 0.98% | +20.6% |
| Q4 2014 | $5,266,000 | -22.5% | 120,000 | 0.0% | 0.81% | -41.9% |
| Q3 2014 | $6,792,000 | +26.1% | 120,000 | 0.0% | 1.40% | -2.1% |
| Q2 2014 | $5,387,000 | +83.7% | 120,000 | +100.0% | 1.43% | +111.7% |
| Q1 2014 | $2,933,000 | – | 60,000 | – | 0.67% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |